Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Hyundai Pharmaceutical Co., Ltd. (004310) Stock Price & Analysis

004310 Stock Chart & Stats

₩6,600.00₩30.00(0.46%)
At close: 3:30 PM GMT+9
₩5K₩7.5K₩10K3 Aug18 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
KRW 6,450.00 - KRW 6,800.00
52-Week Range
KRW 3,500.00 - KRW 15,960.00
Previous Close
KRW 6,680.00
Volume
N/A
Average Volume (3M)
1.01M
Market Cap
KRW 203.12B
Enterprise Value
KRW 224.18B
Total Cash (Recent Filing)
KRW 22.72B
Total Debt (Recent Filing)
KRW 49.54B
Price to Earnings (P/E)
54.4
Beta
0.58
Next Earnings
Feb 18, 2027 (Est.)
EPS Estimate
N/A
Last Dividend Ex-Date
Mar 03, 2026
Dividend Yield
0.46%

Bulls Say, Bears Say

Bulls Say

Revenue Rebound

The strong TTM revenue rebound indicates improving demand and commercial execution after weaker periods. Continued top-line expansion would provide a broader base for operating leverage, product investment, and improved earnings durability over the next several quarters.

Return To Profitability

A return to positive operating profit and net income improves the company’s ability to fund activities internally and reduces dependence on external financing. If maintained, this recovery can establish a more durable earnings base despite the still modest level of profitability.

Healthier Capital Structure

Debt below equity and a larger equity base provide a stronger balance-sheet cushion than in recent annual periods. This improves financial resilience and preserves flexibility to support operations or growth, although the benefit depends on the company converting that capital into stronger returns.

Bears Say

Thin And Uneven Margins

Low single-digit margins leave limited protection against operating setbacks and make earnings sensitive to changes in revenue or expenses. The history of choppy results and prior losses also indicates that the recent recovery has not yet demonstrated consistent, high-quality profitability.

Unreliable Cash Conversion

Positive TTM cash flow is encouraging, but repeated historical periods of negative operating and free cash flow show that earnings have not converted reliably into cash. This volatility can constrain internally funded growth and make liquidity planning more difficult across business cycles.

Recent Free-cash-flow Deterioration

A sharply negative recent free-cash-flow growth rate weakens the quality of the current earnings recovery and may reflect greater working-capital needs or reinvestment. Unless this normalizes, cash available for debt reduction, shareholder returns, and expansion could remain constrained.

004310 FAQ

What was Hyundai Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Hyundai Pharmaceutical Co., Ltd. lowest stock price was ₩3500.00 and its highest was ₩15960.00 in the past 12 months.
What is Hyundai Pharmaceutical Co., Ltd.’s market cap?
Hyundai Pharmaceutical Co., Ltd.’s market cap is ₩203.12B.
When is Hyundai Pharmaceutical Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Hyundai Pharmaceutical Co., Ltd.’s earnings last quarter?
Hyundai Pharmaceutical Co., Ltd. released its earnings results on Oct 15, 2026. The company reported ₩55.35 earnings per share for the quarter.
Is Hyundai Pharmaceutical Co., Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Hyundai Pharmaceutical Co., Ltd. pay dividends?
Hyundai Pharmaceutical Co., Ltd. pays a ― dividend of ₩30 which represents an annual dividend yield of 0.46%. See more information on Hyundai Pharmaceutical Co., Ltd. dividends here
What is Hyundai Pharmaceutical Co., Ltd.’s EPS estimate?
Hyundai Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hyundai Pharmaceutical Co., Ltd. have?
Hyundai Pharmaceutical Co., Ltd. has 32,000,000 shares outstanding.
What happened to Hyundai Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Hyundai Pharmaceutical Co., Ltd. reported an EPS of ₩55.35 in its last earnings report. Following the earnings report the stock price went down -6.596%.
Which hedge fund is a major shareholder of Hyundai Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in KR:004310
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology